Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Asymptomatic Cerebrospinal Fluid HIV-1 Viral Blips and Viral Escape During Antiretroviral Therapy: A Longitudinal Study.

Edén A, Nilsson S, Hagberg L, Fuchs D, Zetterberg H, Svennerholm B, Gisslén M.

J Infect Dis. 2016 Dec 15;214(12):1822-1825. Epub 2016 Sep 28.

PMID:
27683820
2.

HIV-1 low copy viral sequencing-A prototype assay.

Mellberg T, Krabbe J, Gisslén M, Svennerholm B.

Infect Dis (Lond). 2016;48(6):472-6. doi: 10.3109/23744235.2015.1133925. Epub 2016 Jan 14.

PMID:
26763384
3.

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, Van de Vijver DAMC, Åsjö B, Beshkov D, Coughlan S, Descamps D, Griskevicius A, Hamouda O, Horban A, Van Kasteren M, Kolupajeva T, Kostrikis LG, Liitsola K, Linka M, Mor O, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Staneková D, Stanojevic M, Van Laethem K, Zazzi M, Zidovec Lepej S, Boucher CAB, Schmit JC, Wensing AMJ; SPREAD Program, Puchhammer-Stockl E, Sarcletti M, Schmied B, Geit M, Balluch G, Vandamme AM, Vercauteren J, Derdelinckx I, Sasse A, Bogaert M, Ceunen H, De Roo A, De Wit S, Echahidi F, Fransen K, Goffard JC, Goubau P, Goudeseune E, Yombi JC, Lacor P, Liesnard C, Moutschen M, Pierard D, Rens R, Schrooten Y, Vaira D, Vandekerckhove LPR, Van den Heuvel A, Van Der Gucht B, Van Ranst M, Van Wijngaerden E, Vandercam B, Vekemans M, Verhofstede C, Clumeck N, Van Laethem K, Beshkov D, Alexiev I, Lepej SZ, Begovac J, Kostrikis L, Demetriades I, Kousiappa I, Demetriou V, Hezka J, Linka M, Maly M, Machala L, Nielsen C, Jørgensen LB, Gerstoft J, Mathiesen L, Pedersen C, Nielsen H, Laursen A, Kvinesdal B, Liitsola K, Ristola M, Suni J, Sutinen J, Descamps D, Assoumou L, Castor G, Grude M, Flandre P, Storto A, Hamouda O, Kücherer C, Berg T, Braun P, Poggensee G, Däumer M, Eberle J, Heiken H, Kaiser R, Knechten H, Korn K, Müller H, Neifer S, Schmidt B, Walter H, Gunsenheimer-Bartmeyer B, Harrer T, Paraskevis D, Hatzakis A, Zavitsanou A, Vassilakis A, Lazanas M, Chini M, Lioni A, Sakka V, Kourkounti S, Paparizos V, Antoniadou A, Papadopoulos A, Poulakou G, Katsarolis I, Protopapas K, Chryssos G, Drimis S, Gargalianos P, Xylomenos G, Lourida G, Psichogiou M, Daikos GL, Sipsas NV, Kontos A, Gamaletsou MN, Koratzanis G, Sambatakou H, Mariolis H, Skoutelis A, Papastamopoulos V, Georgiou O, Panagopoulos P, Maltezos E, Coughlan S, De Gascun C, Byrne C, Duffy M, Bergin C, Reidy D, Farrell G, Lambert J, O'Connor E, Rochford A, Low J, Coakely P, O'Dea S, Hall W, Mor O, Levi I, Chemtob D, Grossman Z, Zazzi M, de Luca A, Balotta C, Riva C, Mussini C, Caramma I, Capetti A, Colombo MC, Rossi C, Prati F, Tramuto F, Vitale F, Ciccozzi M, Angarano G, Rezza G, Kolupajeva T, Vasins O, Griskevicius A, Lipnickiene V, Schmit JC, Struck D, Sauvageot N, Hemmer R, Arendt V, Michaux C, Staub T, Sequin-Devaux C, Wensing AMJ, Boucher CAB, van de Vijver DAMC, van Kessel A, van Bentum PHM, Brinkman K, Connell BJ, van der Ende ME, Hoepelman IM, van Kasteren M, Kuipers M, Langebeek N, Richter C, Santegoets RMWJ, Schrijnders-Gudde L, Schuurman R, van de Ven BJM, Åsjö B, Kran AB, Ormaasen V, Aavitsland P, Horban A, Stanczak JJ, Stanczak GP, Firlag-Burkacka E, Wiercinska-Drapalo A, Jablonowska E, Maolepsza E, Leszczyszyn-Pynka M, Szata W, Camacho R, Palma C, Borges F, Paixão T, Duque V, Araújo F, Otelea D, Paraschiv S, Tudor AM, Cernat R, Chiriac C, Dumitrescu F, Prisecariu LJ, Stanojevic M, Jevtovic D, Salemovic D, Stanekova D, Habekova M, Chabadová Z, Drobkova T, Bukovinova P, Shunnar A, Truska P, Poljak M, Lunar M, Babic D, Tomazic J, Vidmar L, Vovko T, Karner P, Garcia F, Paredes R, Monge S, Moreno S, Del Amo J, Asensi V, Sirvent JL, de Mendoza C, Delgado R, Gutiérrez F, Berenguer J, Garcia-Bujalance S, Stella N, de Los Santos I, Blanco JR, Dalmau D, Rivero M, Segura F, Elías MJP, Alvarez M, Chueca N, Rodríguez-Martín C, Vidal C, Palomares JC, Viciana I, Viciana P, Cordoba J, Aguilera A, Domingo P, Galindo MJ, Miralles C, Del Pozo MA, Ribera E, Iribarren JA, Ruiz L, de la Torre J, Vidal F, Clotet B, Albert J, Heidarian A, Aperia-Peipke K, Axelsson M, Mild M, Karlsson A, Sönnerborg A, Thalme A, Navér L, Bratt G, Karlsson A, Blaxhult A, Gisslén M, Svennerholm B, Bergbrant I, Björkman P, Säll C, Mellgren Å, Lindholm A, Kuylenstierna N, Montelius R, Azimi F, Johansson B, Carlsson M, Johansson E, Ljungberg B, Ekvall H, Strand A, Mäkitalo S, Öberg S, Holmblad P, Höfer M, Holmberg H, Josefson P, Ryding U.

Clin Infect Dis. 2016 Mar 1;62(5):655-663. doi: 10.1093/cid/civ963. Epub 2015 Nov 29.

4.

Risk of HIV transmission from patients on antiretroviral therapy: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy.

Albert J, Berglund T, Gisslén M, Gröön P, Sönnerborg A, Tegnell A, Alexandersson A, Berggren I, Blaxhult A, Brytting M, Carlander C, Carlson J, Flamholc L, Follin P, Haggar A, Hansdotter F, Josephson F, Karlström O, Liljeros F, Navér L, Pettersson K, Johansson VS, Svennerholm B, Tunbäck P, Widgren K.

Scand J Infect Dis. 2014 Oct;46(10):673-7. doi: 10.3109/00365548.2014.926565. Epub 2014 Jul 30. Review.

5.

Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2013.

Navér L, Albert J, Böttiger Y, Carlander C, Flamholc L, Gisslén M, Josephson F, Karlström O, Lindborg L, Svedhem-Johansson V, Svennerholm B, Sönnerborg A, Yilmaz A, Pettersson K.

Scand J Infect Dis. 2014 Jun;46(6):401-11. doi: 10.3109/00365548.2014.898333. Epub 2014 Apr 22. Review.

PMID:
24754479
6.

Antibody persistence 1 year after pandemic H1N1 2009 influenza vaccination and immunogenicity of subsequent seasonal influenza vaccine among adult organ transplant patients.

Felldin M, Andersson B, Studahl M, Svennerholm B, Friman V.

Transpl Int. 2014 Feb;27(2):197-203. doi: 10.1111/tri.12237. Epub 2013 Dec 2.

7.

Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy.

Gisslén M, Fuchs D, Hagberg L, Svennerholm B, Zetterberg H.

Scand J Infect Dis. 2012 Dec;44(12):997-1000. doi: 10.3109/00365548.2012.690526. Epub 2012 Jul 9.

8.

The antibody response to pandemic H1N1 2009 influenza vaccine in adult organ transplant patients.

Felldin M, Studahl M, Svennerholm B, Friman V.

Transpl Int. 2012 Feb;25(2):166-71. doi: 10.1111/j.1432-2277.2011.01391.x. Epub 2011 Nov 26.

9.

Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV.

Mellberg T, Gonzalez VD, Lindkvist A, Edén A, Sönnerborg A, Sandberg JK, Svennerholm B, Gisslén M.

AIDS Res Ther. 2011 Jun 28;8:21. doi: 10.1186/1742-6405-8-21.

10.

HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment.

Edén A, Fuchs D, Hagberg L, Nilsson S, Spudich S, Svennerholm B, Price RW, Gisslén M.

J Infect Dis. 2010 Dec 15;202(12):1819-25. doi: 10.1086/657342. Epub 2010 Nov 4.

11.

Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.

Yilmaz A, Verhofstede C, D'Avolio A, Watson V, Hagberg L, Fuchs D, Svennerholm B, Gisslén M.

J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):590-6. doi: 10.1097/QAI.0b013e3181f5b3d1.

PMID:
20847699
12.

Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates.

Karlsson U, Antonsson L, Repits J, Medstrand P, Owman C, Kidd-Ljunggren K, Hagberg L, Svennerholm B, Jansson M, Gisslén M, Ljungberg B.

AIDS Res Hum Retroviruses. 2009 Dec;25(12):1297-1305. doi: 10.1089/aid.2009.0069.

13.

Treatment of HIV infection: Swedish recommendations 2009.

Josephson F, Albert J, Flamholc L, Gisslén M, Karlström O, Moberg L, Navér L, Svedhem V, Svennerholm B, Sönnerborg A; Swedish Medical Products Agency; Swedish Reference Group for Antiviral Therapy.

Scand J Infect Dis. 2009;41(11-12):788-807. doi: 10.3109/00365540903214322. Review.

PMID:
19922061
14.

Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study.

Lindkvist A, Edén A, Norström MM, Gonzalez VD, Nilsson S, Svennerholm B, Karlsson AC, Sandberg JK, Sönnerborg A, Gisslén M.

AIDS Res Ther. 2009 Jul 1;6:15. doi: 10.1186/1742-6405-6-15.

15.

Activity of the small modified amino acid alpha-hydroxy glycineamide on in vitro and in vivo human immunodeficiency virus type 1 capsid assembly and infectivity.

Abdurahman S, Végvári A, Youssefi M, Levi M, Höglund S, Andersson E, Horal P, Svennerholm B, Balzarini J, Vahlne A.

Antimicrob Agents Chemother. 2008 Oct;52(10):3737-44. doi: 10.1128/AAC.00265-08. Epub 2008 Jul 21.

16.

Cerebrospinal fluid viral load and intrathecal immune activation in individuals infected with different HIV-1 genetic subtypes.

Abdulle S, Hagberg L, Svennerholm B, Fuchs D, Gisslén M.

PLoS One. 2008 Apr 16;3(4):e1971. doi: 10.1371/journal.pone.0001971.

17.

Comparison of HIV-1 pol and env sequences of blood, CSF, brain and spleen isolates collected ante-mortem and post-mortem.

Caragounis EC, Gisslén M, Lindh M, Nordborg C, Westergren S, Hagberg L, Svennerholm B.

Acta Neurol Scand. 2008 Feb;117(2):108-16. doi: 10.1111/j.1600-0404.2007.00914.x.

PMID:
18184346
18.

Antiretroviral treatment of HIV infection: Swedish recommendations 2007.

Josephson F, Albert J, Flamholc L, Gisslén M, Karlström O, Lindgren SR, Navér L, Sandström E, Svedhem-Johansson V, Svennerholm B, Sönnerborg A.

Scand J Infect Dis. 2007;39(6-7):486-507. Review.

PMID:
17577810
19.

Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy.

Yilmaz A, Svennerholm B, Hagberg L, Gisslén M.

Antivir Ther. 2006;11(7):833-7.

PMID:
17302245
20.

Kinetics of HIV-1 in cerebrospinal fluid and serum after zidovudine treatment.

Hagberg L, Gisslen M, Norkrans G, Svennerholm B.

J NeuroAIDS. 1999;2(2):29-35.

PMID:
16873191
21.

Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.

Yilmaz A, Ståhle L, Hagberg L, Svennerholm B, Fuchs D, Gisslén M.

Scand J Infect Dis. 2004;36(11-12):823-8.

PMID:
15764168
22.

Glycine-amide is an active metabolite of the antiretroviral tripeptide glycyl-prolyl-glycine-amide.

Andersson E, Horal P, Jejcic A, Höglund S, Balzarini J, Vahlne A, Svennerholm B.

Antimicrob Agents Chemother. 2005 Jan;49(1):40-4.

23.

Cerebrospinal fluid viral load, virus isolation, and intrathecal immunoactivation in HIV type 2 infection.

Arvidson N, Gisslén M, Albert J, Brandin E, Svennerholm B, Fuchs D, Hagberg L.

AIDS Res Hum Retroviruses. 2004 Jul;20(7):711-5.

PMID:
15307916
24.

Obligatory involvement of CD26/dipeptidyl peptidase IV in the activation of the antiretroviral tripeptide glycylprolylglycinamide (GPG-NH(2)).

Balzarini J, Andersson E, Schols D, Proost P, Van Damme J, Svennerholm B, Horal P, Vahlne A.

Int J Biochem Cell Biol. 2004 Sep;36(9):1848-59.

PMID:
15183349
25.

Structural and functional features of the polycationic peptide required for inhibition of herpes simplex virus invasion of cells.

Trybala E, Olofsson S, Mårdberg K, Svennerholm B, Umemoto K, Glorioso JC, Bergström T.

Antiviral Res. 2004 Jun;62(3):125-34.

PMID:
15130536
26.

No cross-resistance or selection of HIV-1 resistant mutants in vitro to the antiretroviral tripeptide glycyl-prolyl-glycine-amide.

Andersson E, Horal P, Vahlne A, Svennerholm B.

Antiviral Res. 2004 Feb;61(2):119-24.

PMID:
14670585
27.
28.

Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection.

Abdulle S, Hagberg L, Svennerholm B, Fuchs D, Gisslén M.

AIDS. 2002 Nov 8;16(16):2145-9.

PMID:
12409735
29.

Application of a colorimetric chain-termination assay for characterization of reverse transcriptase from 3'-azido-2',3'-deoxythymidine-resistant HIV isolates.

Shao XW, Hjalmarsson S, Lennerstrand J, Svennerholm B, Blomberg J, Källander CF, Gronowitz JS.

Biotechnol Appl Biochem. 2002 Jun;35(3):155-64.

PMID:
12074693
30.

A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS.

Bech E, Lycke J, Gadeberg P, Hansen HJ, Malmeström C, Andersen O, Christensen T, Ekholm S, Haahr S, Höllsberg P, Bergström T, Svennerholm B, Jakobsen J.

Neurology. 2002 Jan 8;58(1):31-6.

PMID:
11781402
32.

Monoclonal antibodies and human sera directed to the secreted glycoprotein G of herpes simplex virus type 2 recognize type-specific antigenic determinants.

Liljeqvist JA, Trybala E, Hoebeke J, Svennerholm B, Bergström T.

J Gen Virol. 2002 Jan;83(Pt 1):157-65.

PMID:
11752712
33.
35.
36.

The tripeptide glycyl-prolyl-glycine amide does not affect the early steps of the human immunodeficiency virus type 1 replication.

Su J, Naghavi MH, Jejcic A, Horal P, Furuta Y, Wu YP, Li SL, Hall WW, Goobar-Larsson L, Svennerholm B, Vahlne A.

J Hum Virol. 2001 Jan-Feb;4(1):8-15.

PMID:
11213934
37.

The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1.

Su J, Andersson E, Horal P, Naghavi MH, Palm A, Wu YP, Eriksson K, Jansson M, Wigzell H, Svennerholm B, Vahlne A.

J Hum Virol. 2001 Jan-Feb;4(1):1-7.

PMID:
11213928
38.

Conservation of type-specific B-cell epitopes of glycoprotein G in clinical herpes simplex virus type 2 isolates.

Liljeqvist JA, Svennerholm B, Bergström T.

J Clin Microbiol. 2000 Dec;38(12):4517-22.

39.

Herpes simplex virus types 1 and 2 differ in their interaction with heparan sulfate.

Trybala E, Liljeqvist JA, Svennerholm B, Bergström T.

J Virol. 2000 Oct;74(19):9106-14.

40.

Cerebrospinal fluid and plasma viral load in HIV-1-infected patients with various anti-retroviral treatment regimens.

Gisslén M, Svennerholm B, Norkrans G, Franzén C, Säll C, Svensson R, Oberg S, Hagberg L.

Scand J Infect Dis. 2000;32(4):365-9.

PMID:
10959643
41.

Higher HIV-1 RNA cutoff level required in cerebrospinal fluid than in blood to predict positive HIV-1 isolation.

Andersson LM, Svennerholm B, Hagberg L, Gisslén M.

J Med Virol. 2000 Sep;62(1):9-13.

PMID:
10935982
42.

Increased cerebrospinal fluid protein tau concentration in neuro-AIDS.

Andersson L, Blennow K, Fuchs D, Svennerholm B, Gisslén M.

J Neurol Sci. 1999 Dec 15;171(2):92-6.

PMID:
10581374
43.
44.

Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection.

Gisslén M, Fuchs D, Svennerholm B, Hagberg L.

J Acquir Immune Defic Syndr. 1999 Aug 1;21(4):271-6.

PMID:
10428104
45.

The N-linked glycan of the V3 region of HIV-1 gp120 and CXCR4-dependent multiplication of a human immunodeficiency virus type 1 lymphocyte-tropic variant.

Losman B, Biller M, Olofsson S, Schønning K, Lund OS, Svennerholm B, Hansen JE, Bolmstedt A.

FEBS Lett. 1999 Jul 2;454(1-2):47-52.

46.

Typing of clinical herpes simplex virus type 1 and type 2 isolates with monoclonal antibodies.

Liljeqvist JA, Svennerholm B, Bergström T.

J Clin Microbiol. 1999 Aug;37(8):2717-8. Erratum in: J Clin Microbiol 1999 Nov;37(11):3788.

47.

Neurological efficacy of stavudine, zidovudine, and lamivudine.

Gisslén M, Svennerholm B, Fuchs D, Hagberg L.

Lancet. 1998 Aug 1;352(9125):402-3. No abstract available.

PMID:
9717951
48.

Localization of type-specific epitopes of herpes simplex virus type 2 glycoprotein G recognized by human and mouse antibodies.

Liljeqvist JA, Trybala E, Svennerholm B, Jeansson S, Sjögren-Jansson E, Bergström T.

J Gen Virol. 1998 May;79 ( Pt 5):1215-24.

PMID:
9603337
49.

Cerebrospinal fluid viral load in HIV-1-infected patients without antiretroviral treatment: a longitudinal study.

Gisslén M, Hagberg L, Fuchs D, Norkrans G, Svennerholm B.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):291-5.

PMID:
9525428

Supplemental Content

Loading ...
Support Center